Viberzi costs roughly $1,600 to $1,730 for a 60-tablet supply without insurance, making it one of the pricier prescriptions for irritable bowel syndrome with diarrhea (IBS-D). Several factors drive that price: strong patent protection that blocks generic competition, a billion-dollar acquisition deal behind the drug, its classification as a controlled substance, and a limited patient population that narrows the market.
No Generic Competition Until at Least 2026
The single biggest reason Viberzi costs what it does is that no generic version is available. AbbVie holds 16 patents on eluxadoline (the active ingredient), with expiration dates staggered from March 2025 all the way out to March 2033. At least one generic manufacturer has received tentative FDA approval for a generic version, but the agency cannot grant final approval until a key patent expires in June 2026 at the earliest. Even after that date, additional patents extending to 2028 and 2033 could delay or complicate full generic entry depending on legal challenges.
This patent wall is a common strategy in the pharmaceutical industry. By filing multiple patents covering different aspects of a drug’s formulation, manufacturing process, and mechanism, a company can extend its period of market exclusivity well beyond the original patent. Until generics reach the market, AbbVie has no price competition for Viberzi, giving it full control over pricing.
A Billion-Dollar Acquisition Built Into the Price
Viberzi wasn’t developed in-house by the company that now sells it. In 2014, Actavis (which later became part of AbbVie’s portfolio through the Allergan acquisition) purchased Furiex Pharmaceuticals, the small company that created eluxadoline, for $1.16 billion in cash plus the assumption of debt. On top of that, the deal included up to $360 million in additional payments tied to how the drug would be classified by the DEA.
That acquisition price reflected a bet on Viberzi’s commercial potential. When a company pays over a billion dollars for a single drug candidate before it’s even approved, the eventual retail price needs to recover that investment. The drug received FDA approval in 2015, and pricing has remained high ever since.
Controlled Substance Status Adds Complexity
Viberzi is classified as a Schedule IV controlled substance because it acts on opioid receptors in the gut. While it was designed to work locally in the digestive tract rather than in the brain, abuse potential studies showed it can produce euphoria at higher-than-prescribed doses. In clinical testing with people experienced with recreational opioids, supratherapeutic doses caused euphoria in 14% to 28% of participants, compared to 0% to 5% on placebo.
This scheduling adds regulatory burden at every stage: manufacturing, distribution, prescribing, and dispensing all carry extra requirements. Pharmacies must track it differently, and prescribers face additional documentation. These compliance costs get folded into the overall price. The controlled substance classification also limits how aggressively the drug can be marketed and prescribed, which keeps the patient pool smaller and the per-unit cost higher.
Safety Restrictions Shrink the Market
Viberzi carries a significant safety limitation that further narrows its market. The FDA requires a contraindication for patients without a gallbladder, who face an increased risk of pancreatitis and sphincter of Oddi spasm. Fatal cases have been reported in this group, with most serious reactions occurring within the first week of treatment, sometimes after just one or two doses.
Roughly 600,000 gallbladder removals are performed in the U.S. each year, and many IBS-D patients have already had theirs removed. This contraindication eliminates a substantial chunk of potential users. When a drug serves a smaller eligible population, the manufacturer spreads its fixed costs (research, manufacturing, regulatory compliance) across fewer prescriptions, keeping the per-unit price elevated.
How Viberzi Compares to Alternatives
The cost gap between Viberzi and other IBS-D options is stark. A 100-capsule supply of generic loperamide (the active ingredient in Imodium) costs between $14 and $33. That’s roughly 1% to 2% of what Viberzi costs for a similar treatment period. Loperamide is available over the counter with no prescription needed.
Xifaxan, the other major branded prescription for IBS-D, is even more expensive at about $3,594 for 60 tablets. So while Viberzi is costly, it actually sits in the middle of the branded IBS-D market rather than at the top. The difference is that Xifaxan is typically taken in short courses, while Viberzi is a daily, ongoing medication, which means the annual cost of Viberzi adds up quickly.
What You Might Actually Pay
The wholesale acquisition cost, what pharmacies pay before markup, is about $1,601 for a supply of Viberzi. Without insurance, you’ll pay around $1,732 at retail. But most people don’t pay that full amount.
Insurance coverage varies widely. Within the VA system, for example, Viberzi is non-formulary, meaning it requires prior authorization and a special request before it can be dispensed. Many commercial insurers place it on a specialty or non-preferred tier, which typically means higher copays and prior authorization hoops. Your insurer may require you to try cheaper alternatives like loperamide first before approving Viberzi.
AbbVie offers a savings program for commercially insured patients that can bring the cost down to as little as $30 for a 30-day, 60-day, or 90-day supply, with a maximum annual benefit of $13,714. The catch: the program excludes anyone on Medicare, Medicaid, TRICARE, or other government insurance, and it doesn’t apply to cash-paying patients either. If you have commercial insurance and meet the eligibility requirements, this card can dramatically reduce your out-of-pocket cost.
When Prices Could Drop
The most meaningful price relief will come when generic eluxadoline reaches the market. The earliest that could happen is mid-2026, when a critical patent expires and at least one tentatively approved generic could receive final FDA clearance. However, AbbVie’s later patents extending to 2028 and 2033 could lead to legal battles that delay additional generic competitors. Historically, it takes multiple generic manufacturers entering the market before prices drop substantially, often 80% or more below the brand-name price. Until then, the savings card and insurance negotiation remain the primary ways to reduce what you pay.